Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Valneva (VALN) Stock Rises on Deal With EU for COVID-19 Jab

Valneva (VALN) enters into a supply agreement for its COVID vaccine candidate with the European Commission. The stock price surges following the news.

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer

Biotech Stock Roundup: REGN, MRNA Post Q3 Earnings, SAVA Gains on AD Review Data

Earnings and other updates from bigwigs like Regeneron (REGN) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.

Sweta Killa headshot

7 Stocks With Triple-Digit Gains Powering S&P 500 ETF

The S&P 500 logged in eight consecutive gains, representing its longest winning streak since 2017, and closed above the 4,700 milestone for the first time ever.

Daniel Laboe headshot

The Stock Market Rally Is Back In High Gear

All the major indexes are trading at record levels, but how long can this rally hold us in this extremely overbought state?

Is a Beat in Store for BioNTech (BNTX) This Earnings Season?

On BioNTech's (BNTX) third-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.

Sweta Killa headshot

5 ETFs Sizzling to Start November

ETFs overall gathered about $20 billion capital last week (ending Nov 5), bringing in inflows of more than $739 billion year to date.

Pfizer (PFE) COVID Pill Shows Strong Efficacy, Stock Rallies

Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially

Markets Up on COVID Pill News

Markets Up on COVID Pill News

Mark Vickery headshot

More Good Covid Treatment News; Markets Up Again

The Dow is +140 points, the S&P 500 +10 and the Nasdaq +2 points in the pre-market.

Sweta Killa headshot

Rally in Travel and Tourism ETFs Set to Continue

The solid trend in travel and tourism ETFs are likely to continue heading into the holiday season given the reopening of domestic and international borders for traveling.

Stock Market News for Nov 8, 2021

Benchmarks closed higher on Friday lifted by solid October jobs report and encouraging COVID-19 antiviral drug results from Pfizer.

Nalak Das headshot

Three Encouraging News on U.S. Economic Recovery: 5 Top Picks

We have narrowed down our search to five large-cap growth stocks that have strong growth potential for the rest of 2021. These are: TSLA, NUE, ON, IT and CBRE.

Nektar (NKTR) Q3 Earnings Top, Pipeline Remains On Track

Nektar (NKTR) reports mixed third-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.

Nonfarm Payrolls Jump in October

Nonfarm Payrolls Jump in October.

Aerie's (AERI) Q3 Earnings Miss Estimates, Revenues Rise Y/Y

Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.

Mark Vickery headshot

Huge Jobs Number: 531K, 4.6% Unemployment; Did Pfizer Cure Covid?

The private sector alone brought 604K jobs, more than a third of which came from the Leisure & Hospitality and Professional & Business Services sectors.

The Zacks Analyst Blog Highlights: Nucor, Dow, Pfizer, Costco and Lowe's

The Zacks Analyst Blog Highlights: Nucor, Dow, Pfizer, Costco and Lowe's

Should Principal U.S. MegaCap ETF (USMC) Be on Your Investing Radar?

Style Box ETF report for USMC

Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss

Corcept's (CORT) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company tightens its revenue guidance for 2021.

Nalak Das headshot

Fed Chair Speaks in Cautious Tone Despite Tapering: 5 Picks

Each of our large-cap picks carries either a Zacks Rank #1 (Strong Buy) or 2 (Buy) and has a VGM Score of A. These are: NUE, PFE, DOW, COST and LOW.

PFE vs. LLY: Which Stock Should Value Investors Buy Now?

PFE vs. LLY: Which Stock Is the Better Value Option?

Is Pfizer (PFE) Stock Outpacing Its Medical Peers This Year?

Is (PFE) Outperforming Other Medical Stocks This Year?

Amarin (AMRN) Q3 Earnings Top, Vascepa Sales Decline Y/Y

Amarin's (AMRN) reports lower sales volume for its drug, Vascepa, in the United States during the third quarter. The company's stock falls in pre-market trading.

Better-Than-Expected Private Payrolls in October

Better-Than-Expected Private Payrolls in October.